Krystal Biotech has built a franchise with wide moat characteristics — 54% net margins, a Rule of 40 score of 65, and a near-perfect Piotroski score of 9 out of 9 — and three consecutive earnings beats confirm the growth trajectory is intact; however, the stock has reached its near-term resistance target with effectively no remaining price headroom, and single-product concentration means any adverse development would impact the entire revenue base simultaneously.
Thesis pillars
- Wide Moat Elite Profitability→Stable
- Sustained Earnings Beat Streak↑Improving
- Single Product Concentration↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Krystal Biotech, Inc. (KRYS) Stock Analysis
Range Bound setup · Catalyst-Driven edge
Healthcare · Biotechnology
Wait for pullback to $302.77. At $330.69 the A.R:R is 0.5:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $302.77 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: VYJUVEK; Thin upside margin: 3.2%.
Krystal Biotech develops genetic medicines using an engineered HSV-1 platform, with VYJUVEK as its sole commercial product approved in the U.S. (2023), EU, and Japan (both 2025) for dystrophic epidermolysis bullosa. Since the 2023 U.S. launch, VYJUVEK has generated $730.3... Read more
Wait for pullback to $302.77. At $330.69 the A.R:R is 0.5:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $302.77 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: VYJUVEK; Thin upside margin: 3.2%. Chart setup: RSI 41 mid-range, Bollinger mid-band. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.89, quality 8.1/10, growth 9.2/10). Score 6.2/10, moderate confidence.
Passes 5/8 gates (no SEC red flags, news events none recent, earnings proximity 18d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: speculative.
About Krystal Biotech, Inc.
About Krystal Biotech, Inc.
VYJUVEK (beremagene geperpavec), the first-ever redosable gene therapy, generated $730.3 million in cumulative net product revenue since Krystal Biotech's U.S. launch in 2023 through fiscal year 2025. FDA approved VYJUVEK in May 2023 for dystrophic epidermolysis bullosa in patients six months and older; the European Commission granted marketing authorization in April 2025 and Japan's MHLW in July 2025, targeting an estimated 3,000 U.S. patients and over 9,000 worldwide. The company operates two in-house commercial-scale CGMP facilities in Pennsylvania.
Krystal Biotech commercializes VYJUVEK directly in the United States, major European markets, and Japan, and contracts with specialty distributors for territories including Central and Eastern Europe, the Middle East, Turkey, and Israel. Germany pricing negotiations are expected to continue through at least the second half of 2026; France pricing negotiations under the Accès Précoce program are expected to continue through 2027; and Italy launch discussions target the second half of 2026. Pipeline candidates include KB407, an inhaled gene therapy for cystic fibrosis in Phase 1 (CORAL-1), which reported positive Cohort 3 data in January 2026 and plans to initiate a potentially registrational CORAL-3 study in the first half of 2026; and KB408, targeting alpha-1 antitrypsin deficiency lung disease in Phase 1 (SERPENTINE-1), where a repeat-dose cohort was initiated in August 2025. The Inflation Reduction Act's Medicare drug-price negotiation provisions and subsequent executive orders directing additional drug pricing reforms add regulatory uncertainty to future VYJUVEK reimbursement conditions.
Show full overview
Krystal Biotech's financial performance rests on a single approved therapy: the 10-K states the company's near-term prospects and future growth are 'substantially dependent on the commercial success of VYJUVEK.' The BPCIA establishes a 12-year biologic exclusivity period from the May 2023 FDA approval, though competing biologics license applications may proceed independently during this window. The One Big Beautiful Bill Act, signed July 4, 2025, reduced Medicaid funding in ways that could affect patient access to high-cost gene therapies, adding a payer-access dimension to the single-product revenue risk.
See also: Healthcare · Biotechnology
From Krystal Biotech, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-15Recent Developments — Krystal Biotech, Inc.
Latest news
- NEWS Krystal Biotech: International Expansion And A Vibrant Pipeline (NASDAQ:KRYS) - Seeking Alpha — Seeking Alpha positive
- NEWS Krystal Biotech: Profitable, Self-Funding, And Loaded With Optionality (NASDAQ:KRYS) - Seeking Alpha — Seeking Alpha positive
- NEWS KRYS|Krystal Biotech Inc|Price:367.180|Chg%:+3.900 - TradingKey — TradingKey positive
- NEWS Earnings Preview: KRYS to Report Financial Results Pre-market on August 03 - Moomoo — Moomoo neutral
- NEWS Krystal Biotech, Inc. (KRYS) earnings expected to grow: What to know ahead of next week's release - MSN — MSN positive
Generated 2026-10-15T11:32:14Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductVYJUVEK10-K Item 1A: 'our near-term prospects...are substantially dependent on the commercial success of VYJUVEK'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $302.77. At $330.69 the A.R:R is 0.5:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $302.77 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: VYJUVEK; Thin upside margin: 3.2%. Chart setup: RSI 41 mid-range, Bollinger mid-band. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.89, quality 8.1/10, growth 9.2/10). Target $341.14 (+3.2%), stop $281.75 (−17.4%), A.R:R 0.5:1. Score 6.2/10, moderate confidence.
Take-profit target: $341.14 (+3.2% upside). Target $341.14 (+3.2%), stop $281.75 (−17.4%), A.R:R 0.5:1. Stop-loss: $281.75.
Concentration risk — Product: VYJUVEK; Thin upside margin: 3.2%; Expensive valuation.
Krystal Biotech, Inc. trades at a P/E of 40.2 (forward 34.7). TrendMatrix value score: 3.5/10. Verdict: Buy (Wait for Entry).
19 analysts cover KRYS with a consensus score of 4.3/5. Average price target: $392.
What does Krystal Biotech, Inc. do?Krystal Biotech develops genetic medicines using an engineered HSV-1 platform, with VYJUVEK as its sole commercial...
Krystal Biotech develops genetic medicines using an engineered HSV-1 platform, with VYJUVEK as its sole commercial product approved in the U.S. (2023), EU, and Japan (both 2025) for dystrophic epidermolysis bullosa. Since the 2023 U.S. launch, VYJUVEK has generated $730.3 million in cumulative net product revenue. Two in-house commercial-scale CGMP manufacturing facilities in Pennsylvania support worldwide supply.